RiesLAG, MelbertD, KrapchoM et al., eds. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
RiesLAGMelbertDKrapchoM, eds. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
)| false
HricakH, DemasBE, WilliamsRD et al.. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology1985;154:709–715.
HricakHDemasBEWilliamsRD. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology1985;154:709–715.
)| false
DechetCB, ZinckeH, SeboTJ et al.. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol2003;169:71–74.
DechetCBZinckeHSeboTJ. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol2003;169:71–74.
)| false
HollingsworthJM, MillerDC, DunnRL et al.. Surgical management of low-stage renal cell carcinoma: technology does not supersede biology. Urology2006;67:1175–1180.
HollingsworthJMMillerDCDunnRL. Surgical management of low-stage renal cell carcinoma: technology does not supersede biology. Urology2006;67:1175–1180.
)| false
LeibovichBC, BluteML, ChevilleJC et al.. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol2004;17:1066–1070.
LeibovichBCBluteMLChevilleJC. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol2004;17:1066–1070.
)| false
RouviereO, BouvierR, NegrierS et al.. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up. Nat Clin Pract Oncol2006;3:200–213.
RouviereOBouvierRNegrierS. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up. Nat Clin Pract Oncol2006;3:200–213.
)| false
MessingEM, ManolaJ, WildingG et al.. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol2003;21:1214–1222.
MessingEMManolaJWildingG. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol2003;21:1214–1222.
)| false
ClarkJI, AtkinsMB, UrbaWJ et al.. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J Clin Oncol2003;21:3133–3140.
ClarkJIAtkinsMBUrbaWJ. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J Clin Oncol2003;21:3133–3140.
)| false
FlaniganRC, MickischG, SylvesterR et al.. Cytoreductive nephrectomy in patients with metastatic renal cancer. A combined analysis. J Urol2004;171:1071–1076.
FlaniganRCMickischGSylvesterR. Cytoreductive nephrectomy in patients with metastatic renal cancer. A combined analysis. J Urol2004;171:1071–1076.
)| false
FlaniganRC, SalmonSE, BlumensteinBA et al.. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med2001;345:1655–1659.
FlaniganRCSalmonSEBlumensteinBA. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med2001;345:1655–1659.
)| false
MickischGH, GarinA, van PoppelH et al.. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet2001;358:966–970.
MickischGHGarinAvan PoppelH. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet2001;358:966–970.
)| false
NegrierS, EscudierB, LassetC et al.. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med1998;338:1273–1278.
NegrierSEscudierBLassetC. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med1998;338:1273–1278.
)| false
YangJC, SherryRM, SteinbergSM et al.. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol2003;21:3127–3132.
YangJCSherryRMSteinbergSM. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol2003;21:3127–3132.
)| false
DutcherJP, FisherRI, WeissG et al.. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am1997;3:157–162.
DutcherJPFisherRIWeissG. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am1997;3:157–162.
)| false
MotzerRJ, BasikJ, MurphyBA et al.. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol2002;20:289–296.
MotzerRJBasikJMurphyBA. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol2002;20:289–296.
)| false
FaivreS, DelbaldoC, VeraK et al.. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol2006;24:25–35.
FaivreSDelbaldoCVeraK. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol2006;24:25–35.
)| false
WilhelmSM, CarterC, TangL et al.. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res2004;64:7099–7109.
WilhelmSMCarterCTangL. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res2004;64:7099–7109.
)| false
MooreM, HirteHW, SiuL et al.. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol2005;16:1688–1694.
MooreMHirteHWSiuL. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol2005;16:1688–1694.
)| false
StrumbergD, RichlyH, HilgerRA et al.. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol2005;23:965–972.
StrumbergDRichlyHHilgerRA. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol2005;23:965–972.
)| false
AwadaA, HendliszA, GilT et al.. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer2005;92:1855–1861.
AwadaAHendliszAGilT. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer2005;92:1855–1861.
)| false
ClarkJW, EderJP, RyanD et al.. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res2005;11:5472–5480.
ClarkJWEderJPRyanD. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res2005;11:5472–5480.
)| false
SzczylikT, DemkowM, StaehlerF et al.. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol2007;25(18S):5025.
SzczylikTDemkowMStaehlerF. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol2007;25(18S):5025.
)| false
GibbonsJJ, DiscafaniC, PetersonR. The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract]. Proc Am Assoc Cancer Res1999;40:Abstract 301.
GibbonsJJDiscafaniCPetersonR. The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract]. Proc Am Assoc Cancer Res1999;40:Abstract 301.
)| false
YangJC, HaworthL, SherryRM et al.. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med2003;349:427–434.
YangJCHaworthLSherryRM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med2003;349:427–434.
)| false
EscudierB, PluzanskaA, KoralewskiP et al.. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007;370:2103–2111.
EscudierBPluzanskaAKoralewskiP. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007;370:2103–2111.
)| false
WenzelC, LockerG, SchmidingerM et al.. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney2002;39:48–54.
WenzelCLockerGSchmidingerM. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney2002;39:48–54.
)| false
StadlerWM, HalabiS, ErnstoffMS et al.. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 4515.
StadlerWMHalabiSErnstoffMS. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 4515.
)| false
MotzerRJ, EscudierB, OudardS et al.. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet2008;372:449–456.
MotzerRJEscudierBOudardS. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet2008;372:449–456.
)| false
RatainMJ, EisenT, StadlerWM et al.. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol2006;24:2505–2512.
RatainMJEisenTStadlerWM. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol2006;24:2505–2512.
)| false
EisenT, BukowskiRM, StaehlerM et al.. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival [abstract]. J Clin Oncol2006;24(Suppl 1): Abstract 4524.
EisenTBukowskiRMStaehlerM. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival [abstract]. J Clin Oncol2006;24(Suppl 1): Abstract 4524.
)| false
BukowskiRM, EisenT, SzczylikC et al.. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 5023.
BukowskiRMEisenTSzczylikC. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 5023.
)| false
